News
Rho to Coordinate Study Sponsored by NIAID to Assess Systemic Allergic Reactions to Pfizer and Moderna COVID-19 Vaccines
Read More
Recent News at Rho
Advancing science, earning recognition
News
In the News: Rho Granted Extension by NIAID to Study Rate of COVID-19 Infection in US Children
Read More
News
Business NC Recognizes Top Industry Leaders, Including CEO, Dr. Laura Helms Reece, in a Fast Growing Life-Sciences Scene
Read More
News
Durham Magazine Recognizes CEO, Dr. Laura Helms Reece in RTP’s Growing Class of Women Leaders
Read More
News
Drug Discovery News: Shifting the execution of studies from clinic-focused to more patient-focused.
Read More
News
Applied Clinical Trials: Plan the Flow of Data Early for Maximum Effect
Read More
News
Marne Boca, a CRA at Rho, shares her perspective on COVID-19’s impact
Read More
News
Navigating a Decentralized Trial Model and the Changing Clinical Landscape During COVID-19
Read More
News
Rho Joins Decentralized Trials Alliance (DTRA)
Read More
News
Applied Clinical Trials Features Marina Acosta Enslen’s Thoughts on Covid-19 Forcing Companies to Comply with the New E6 (R2) Guidelines
Read More
Breaking New Ground in Food Allergy Treatment: Xolair Approval
Nicole Rogers, Associate Director, Project Management, shares a powerful perspective on what it means to be part of the OUtMATCH study, a groundbreaking food allergy study that supported the approval of Xolair.
Clinical Trial Enrollment Caps: What They Are and When to Use Them
What’s the secret to optimizing your clinical trial? It could be understanding enrollment caps and knowing exactly when to set them.
Breathing New Insights: Exploring the Dynamic Connection Between Lung Function, Allergy and Wheezing in Urban Children
Cindy Visness, PhD, Rho’s Principal Research Scientist, worked with investigators on the NIAID-funded Urban Environment and Childhood Asthma (URECA) study to dissect the complex web of factors influencing respiratory health in city-living children in the article, “Relationships between lung function, allergy, and wheezing in urban children” available in The Journal of Allergy and Clinical Immunology April edition.
Tips to Rescue a Clinical Trial Before It’s Too Late
Sometimes relationships can continue even when things aren’t working out. However, when it comes to the partnership between a sponsor and its contract research organization (CRO), there isn’t any time to waste. Failing to address issues quickly during a clinical trial can cause issues.
Unlocking sleep’s role in PTSD
Ben Vaughn, Rho’s Chief Strategist, Biostatistics & Protocol Design, supports Tonix Pharmaceutical’s analyses of how sleep disturbances impact posttraumatic stress disorder (PTSD). Their research sheds light on a novel treatment, TNX-102 SL, which targets sleep quality and emotional memory processing.
Understanding GDPR Compliance in Clinical Trials
Dive into the complexities of GDPR compliance in clinical trials in Contract Pharma’s article, Understanding GDPR Compliance in Clinical Trials, an interview with Laura Gatavs, Head of Legal Department for Rho EU. Explore the nuances of when and where GDPR applies, grasp the basics of compliance – both at company compliance level and when negotiating clinical trial agreements – and uncover essential takeaways and best practices for clinical trial sponsors.
Tonix Pharmaceuticals Announces Engagement of Rho as CRO to Support Submission of New Drug Application to the FDA for Approval of Tonmya™ for the Management of Fibromyalgia
Rho is thrilled to announce our unwavering support for Tonix Pharmaceuticals as they prepare to submit their New Drug Application (NDA). Serving as a dedicated partner to Tonix, we are committed to providing the necessary resources and expertise to support the next steps toward regulatory approval of Tonmya™ for the management of fibromyalgia. Our collaboration underscores our shared dedication to advancing healthcare solutions that improve patient outcomes and enhance the quality of life. We are grateful to be a part of such an exciting partnership as we continue to champion breakthrough advancements in drug development.